Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Persistent activation of the Interleukin-6/Signal Transducer and Activator of Transcription 3 (IL-6/STAT3) signaling pathway is implicated in various human cancers, including breast cancer, colon cancer, and multiple myeloma.
• While IL-6/STAT3 is a promising therapeutic target, there is a lack of highly efficient, specific, and safe STAT3 inhibitors for clinical use.
• Evista (Raloxifene·HCl), a selective estrogen receptor modulator approved for osteoporosis and breast cancer risk reduction, previously showed potential in inhibiting IL-6/GP130 interaction.

Purpose of the Study:

• To investigate the effects of Evista on the IL-6/GP130/STAT3 signaling pathway and cancer cell viability.
• To determine the specificity of Evista's inhibitory action on STAT3 phosphorylation compared to other STAT family members and signaling pathways.

Main Methods:

• Evista's effect on constitutive and IL-6-induced STAT3 phosphorylation was assessed in various cancer cell lines (MDA-MB-231, HCT116, U266, MCF-7, HT29, MM.1S).
• Apoptosis induction was measured via caspase-3 cleavage.
• The specificity of Evista was tested against STAT1, STAT2, STAT4, and STAT6 phosphorylation induced by different cytokines (IFN-α, IFN-γ, IL-4) and against STAT3 phosphorylation induced by Leukemia Inhibitory Factor (LIF).
• STAT3 transcriptional activity and cell viability in vitro were also evaluated.

Main Results:

• Evista demonstrated inhibition of constitutive STAT3 activation in MDA-MB-231, HCT116, and U266 cells.
• Evista suppressed IL-6-induced STAT3 phosphorylation in MCF-7, HT29, and MM.1S cells, and induced apoptosis in MDA-MB-231, HCT116, and U266 cells.
• Crucially, Evista did not inhibit phosphorylation of STAT1, STAT2, STAT4, or STAT6, nor STAT3 phosphorylation induced by LIF, indicating high specificity for the IL-6/STAT3 pathway.
• Evista attenuated STAT3 transcriptional activity and decreased cancer cell viability in vitro.

Conclusions:

• Evista exhibits specific inhibitory effects on the IL-6/STAT3 signaling pathway.
• These findings suggest Evista's potential as a chemoprevention agent for breast cancer, colon cancer, and multiple myeloma by targeting the IL-6/STAT3 pathway.